Items tagged with Vaccines
For decades, researchers have tried to develop broadly effective vaccines to prevent the spread of illnesses such as HIV, malaria, and tuberculosis. While limited progress has been made along these lines, there are still no licensed vaccinations available that can protect most people from these devastating diseases.
Thanks to an infected hospital worker, hundreds of babies in Texas are being tested for TB. Why has it been so hard to develop an effective vaccine for the disease?
SEATTLE, Nov. 19, 2014: With the goal of developing a thermostable tuberculosis vaccine that is resistant to damage from excessive heat or cold, IDRI (Infectious Disease Research Institute) today announces it has been awarded a contract from the National Institute of Allergy and Infectious Diseases, a part of the National Institutes of Health. The contract (HHSN272201400041C) has a base award of $3.6 million and could be worth up to $11.9 million if all milestone-driven options are exercised. The contract provides funding for a team of IDRI scientists – led by Christopher Fox, Ph.D. – to develop, produce and test a thermostable lyophilized formulation of its vaccine candidate to prevent tuberculosis. TB-causing bacteria infect an estimated one-third of the global population, and, in 2013, approximately nine million people developed active cases of TB illness.
Valneva announces publication of first Phase II data of tuberculosis vaccine candidate formulated with IC31® adjuvant (post)
Clinical trial in HIV-infected adults showed good safety and immunogenicity
Developments in oral immunization delivery viewed as potential weapon to combat global health threats such as tuberculosis, AIDS and diarrheas
The TBVI consortium has been granted 24.6 million euros from the European Commission H2020 framework programme (€18.2 mln.) and several institutions as well as national governments outside the EC, among others Switzerland, South Korea and Australia. With this grant the new TBVAC2020 project will be funded, so TBVI can continue its efforts to discover and develop new tuberculosis vaccines.
We need a global strategy for the development of better tuberculosis vaccines.
Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial (post)
For 80 years there was essentially a lull in tuberculosis research. Indeed, the last scientific breakthrough in 1921, the Bacillus Calmette-Guérin (BCG) vaccine, still forms the central pillar of tuberculosis prevention. In most cases, immunisation with BCG protects children from the worst forms of the disease, but not against the most common form, pulmonary tuberculosis in adults and children. The vaccine has therefore not helped to reduce the number of tuberculosis cases. Only since the start of the new millennium has research once again been able to report significant advances in the development of new vaccines and drugs.
The only tuberculosis vaccine currently approved, the Bacillus Calmette-Guérin (BCG) vaccine, protects children from the most severe forms of the disease in most cases but does not provide protection against the most common form, pulmonary tuberculosis in adults and children. BCG has therefore been unable to contain tuberculosis worldwide. Scientists led by Stefan Kaufmann of the Max Planck Institute for Infection Biology in Berlin are therefore working feverishly on a more effective replacement for BCG. The vaccine candidate they have developed, dubbed VPM1002, will now be tested in a large-scale phase II trial with newborns. VPM1002 is a genetically modified variant of the Bacillus Calmette-Guérin (BCG) vaccine. Moreover, another trial will test whether VPM1002 is effective in the treatment of cancer of the bladder.
Page 3 of 19 · Total posts: 0←First 2 3 4 Last→